Literature DB >> 33425717

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma.

Marij J P Welters1, Saskia J Santegoets1, Sjoerd H van der Burg1.   

Abstract

Oropharyngeal squamous cell carcinoma (OPSCC) develops as a consequence of several mutations in the tumor suppressor pathways or after a progressive infection with high risk human papillomavirus (HPV). The dismal side effects of the current standard of care and the clear involvement of the immune system has led to a surge in clinical trials that aim to reinforce the tumor-specific immune response as a new treatment option. In this review, we have focused on the most recent literature to discuss the new findings and insights on the role of different immune cells in the context of OPSCC and its etiology. We then applied this knowledge to describe potential biomarkers and analyzed the rationale and outcomes of earlier and ongoing immunotherapy trials. Finally, we describe new developments that are still at the preclinical phase and provide an outlook on what the near future may bring, now that several new and exciting techniques to study the immune system at the single cell level are being exploited.
Copyright © 2020 Welters, Santegoets and van der Burg.

Entities:  

Keywords:  T cells; clinical outcome; immunotherapy; myeloid cells; oropharyngeal cancer; survival; tumor microenvironment

Year:  2020        PMID: 33425717      PMCID: PMC7793705          DOI: 10.3389/fonc.2020.545385

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  7 in total

Review 1.  Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment.

Authors:  Jeong-Yeon Mun; Sun-Hee Leem; Jun Ho Lee; Hyuk Soon Kim
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

2.  The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.

Authors:  Anna Tosi; Beatrice Parisatto; Paolo Boscolo-Rizzo; Antonio Rosato; Anna Menegaldo; Giacomo Spinato; Maria Guido; Annarosa Del Mistro; Rossana Bussani; Fabrizio Zanconati; Margherita Tofanelli; Giancarlo Tirelli
Journal:  J Exp Clin Cancer Res       Date:  2022-09-20

3.  Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.

Authors:  Simin Li; Yang Wang; Rui Sun; Debora Franceschi; Hongying Pan; Chenxuan Wei; Anthony Chukwunonso Ogbuehi; Bernd Lethaus; Vuk Savkovic; Sebastian Gaus; Rüdiger Zimmerer; Dirk Ziebolz; Gerhard Schmalz; Xiao Jiang
Journal:  J Immunol Res       Date:  2022-09-16       Impact factor: 4.493

Review 4.  Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma.

Authors:  Anders Näsman; Stefan Holzhauser; Ourania N Kostopoulou; Mark Zupancic; Andreas Ährlund-Richter; Juan Du; Tina Dalianis
Journal:  Viruses       Date:  2021-05-14       Impact factor: 5.048

Review 5.  Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors.

Authors:  Peter L Stern; Tina Dalianis
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

Review 6.  CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion.

Authors:  Gurcan Gunaydin
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

Review 7.  HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.

Authors:  Matt Lechner; Jacklyn Liu; Liam Masterson; Tim R Fenton
Journal:  Nat Rev Clin Oncol       Date:  2022-02-01       Impact factor: 65.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.